Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain

María Teresa Martínez Larrad1,2, Arturo Corbatón Anchuelo1,2, Cristina Fernández Pérez1,2, Milagros Pérez Barba2, Yera Lazcano Redondo1,2, Manuel Serrano Ríos1,2*, Segovia Insulin Resistance Study Group (SIRSG)¶

1 Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain, 2 Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC-HCSC), Madrid, Spain

¶ Membership of the SIRSG is provided in the Acknowledgments.

* manuel.serrano@salud.madrid.org; uinvest7.hcsc@salud.madrid.org

Abstract

Objectives

Our aim was to investigate if genetic variations in the visfatin gene (SNPs rs7789066/rs11977021/rs4730153) could modify the cardiovascular-risk (CV-risk) despite the metabolic phenotype (obesity and glucose tolerance). In addition, we investigated the relationship between insulin sensitivity and variations in visfatin gene.

Material and Methods

A population-based study in rural and urban areas of the Province of Segovia, Spain, was carried out in the period of 2001–2003 years. A total of 587 individuals were included, 25.4% subjects were defined as obese (BMI ≥30 Kg/m²).

Results

Plasma visfatin levels were significantly higher in obese subjects with DM2 than in other categories of glucose tolerance. The genotype AA of the rs4730153 SNP was significantly associated with fasting glucose, fasting insulin and HOMA-IR (Homeostasis model assessment-insulin resistance) after adjustment for gender, age, BMI and waist circumference.

The obese individuals carrying the CC genotype of the rs11977021 SNP showed higher circulating levels of fasting proinsulin after adjustment for the same variables.

The genotype AA of the rs4730153 SNP seems to be protective from CV-risk either estimated by Framingham or SCORE charts in general population; and in obese and non-obese individuals. No associations with CV-risk were observed for other studied SNPs (rs11977021/rs7789066).
Conclusions

In summary, this is the first study which concludes that the genotype AA of the rs4730153 SNP appear to protect against CV-risk in obese and non-obese individuals, estimated by Framingham and SCORE charts. Our results confirm that the different polymorphisms in the visfatin gene might be influencing the glucose homeostasis in obese individuals.

Introduction

Nowadays obesity has become epidemic in developed and even in developing countries worldwide [1]. This disease is characterized by low-grade systemic inflammation [2]. Regarding this affirmation, it is fully accepted that the adipose tissue is a metabolically active endocrine organ secreting a variety of bioactive substances known as adipokines, that could act as functional links between energy balance and insulin resistance [3, 4]. Visfatin is a recently described adipokine, also known as pre-B cell colony-enhancing factor (PBEF) or nicotinamide phosphoribosyl transferase (NAMPT)[5]. NAMPT was cloned by Samal and his colleagues in 1994 from activated human peripheral blood lymphocytes during their attempt to discover new factors for the earliest events in B-cell development [6]. This protein of 52-55 KDa, was described as a growth factor for early B cells called pre-B cell colony-enhancing factor 1 (PBEF1).

Recently, it has been identified as an intracellular enzyme and called nicotinamide 5-phosphoribosyl-1-pyrophosphate transferase (NAMPT) that catalyzes the rate-limiting step in nicotinamide adenine dinucleotide (NAD) biosynthesis and mediates the conversion of nicotinamide to nicotinamide mononucleotide [7-9]. It has been proposed that this adipose derived hormone exerts insulin mimicking effects and play a positive role in attenuating insulin resistance. However, the precise mechanisms underlying the beneficial effects of visfatin on insulin sensitivity remain largely unknown [3]. It has been suggested that visfatin might have both endocrine [7,10] and paracrine effects [11], mostly related to obesity and insulin sensitivity although there are important discrepancies in the literature[12]. As regards to obesity, Fukuhara et al. reported that, in adipose tissue, visfatin is predominantly expressed by visceral fat as estimated by abdominal computed tomography; and also its circulating levels correlate with the amount of visceral fat in both humans and mice [7]. However, these observations were not confirmed by other authors [13-15]. Furthermore, the significance of the correlation between visfatin levels and body mass index (BMI) is still unclear [15-17] probably due to deficiencies in the specificity of the applied immunoassays [18].

As it relates to the impact of visfatin on insulin sensitivity, Fukuhara et al reported that, in adipose tissue, visfatin binds to and activates the insulin receptor explaining the reported metabolic effect of this cytokine on peripheral organs [7]. Recently, these authors retracted from the original paper [19], being this hypothesis currently under debate [12]. Moreover, other groups have reported on the presumed insulin mimetic effects of visfatin in osteoblasts and cultured mesangial cells [10,20]. Visfatin is a proinflammatory mediator and might participate in a variety of inflammatory conditions, such as autoimmune diseases and adipose tissue inflammation-induced insulin resistance [21].

The human visfatin gene is located on chromosome 7q22.3 and includes 11 exons encompassing 34.7 kb. Interestingly, this region appears to be linked to metabolic syndrome–related phenotypes in several populations including non diabetic Mexican-Americans [22], Mexicans–American families [23] and hypertensive Hispanic families [24] according to multipoint variance component analysis. Our aim was to investigate if genetic variations in the visfatin gene
could be associated with obesity, glucose tolerance (Diabetes Mellitus Type 2) and cardiovascular (CV) risk–related alterations on a large sample of a population–based study in Spain.

Methods
Participants
The Segovia Study was designed as a cross-sectional, population–based survey of the prevalence of anthropometric and physiological parameters related to obesity and other components of the metabolic syndrome. It was conducted in rural and urban areas of the province of Segovia, in Central Spain. A detailed report of this study has been previously published [25]. In brief, a random sample of 2,992 men and non–pregnant women aged 35–74 years were selected from a target population of 63,417 inhabitants. A total of 587 individuals gave written consent after receiving detailed information on the purposes and the objectives of the study. The protocol was approved by the Ethics Committee of the Hospital Clínico San Carlos in Madrid.

Anthropometrical and biochemical measurements
The BMI and waist circumference (WC) were used as estimations of total body fat mass and visceral obesity, respectively. Those individuals with a BMI higher than 30 kg/m² were classified as obese. Systolic and diastolic blood pressures were measured three times in a seated position after 10 min of rest to the nearest even digit using a random-zero sphygmomanometer. 20 ml of blood were obtained from an antecubital vein without compression after about a ten-hour overnight period. Plasma glucose was determined twice by a glucose-oxidase method adapted to autoanalyze (Hitachi 704, Boehringer Mannheim, Germany). An oral glucose tolerance test (OGTT) was performed following the criteria of the American Diabetes Association [26]. The categories of glucose values were as follows: 1) normoglycaemia (NG): fasting plasma glucose < 100 mg/dl or 2-h postload glucose lower than 140 mg/dl; 2) impaired fasting glucose (IFG): fasting plasma glucose levels ≥ 100 mg/dl but < 126 mg/dl and 2h postload glucose lower than 140 mg/dl; 3) impaired glucose tolerance (IGT): 2-h postload glucose between 140 and 200 mg/dl; 4) diabetes: fasting plasma glucose levels ≥ 126 mg/dl or 2-h postload glucose ≥ 200 mg/dl. Total serum cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL-C) were determined by enzymatic methods using commercial kits (Boehringer Mannheim, Germany). Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula. Plasma visfatin concentrations were measured with a human visfatin (COOH-terminal) enzyme immunometric assay (Phoenix, Belmont, CA). The minimum detectable concentration was 2.3 ng/ml and the intra / inter-assay variation’s coefficient < 5% and < 14% respectively. Insulin, proinsulin, leptin and adiponectin serum concentrations were determined by highly specific / sensitive RIAs (Linco Research Inc., St LouisMO, USA). Insulin resistance (IR) was estimated by the homeostasis model assessment (HOMA-IR) method according to the formula: insulin (µU/ml) x glucose (mmol/l) / 22.5 [27], using a cut-off point for HOMA-IR ≥ 3.8 as described in the Spanish population [28].

To estimate high CV risk we chose: a) Framingham chart by D’Agostino et al [29] in which the top sex–specific quintiles of predicted CVD risk identifies ~ 48% of men and 58% of women who experienced a first CVD event on follow-up (sensitivity) and proportions of men and women without events who were not in the top quintile of risk were 85% and 83% respectively (specificity); b) SCORE Cholesterol risk chart for low risk regions [30]: the 5% threshold has a 35% sensitivity and 88% specificity and the ROC area is 0.74 (95%CI 0.72–0.76). A CVR ≥ 20% according to the Framingham chart is associated with high risk of cardiovascular morbidity and a CVR ≥ 5% with the SCORE chart indicates high risk of cardiovascular mortality.
Genotyping

Three previously described (http://www.ncbi.nlm.nih.gov/SNP) visfatin gene variants were genotyped. In order to select the polymorphic sites in the NAMPT gene that would be genotyped in our sample, we used information from the HapMap database. Previous studies have reported association of NAMPT variants with homeostasis glucose, fasting insulin [17, 31–33] and metabolic disorders [34]. Among these, the SNPs rs7789066 and rs11977021 reside within the promoter region and the SNP rs4730153 is located in an intronic region. DNA was extracted from venous blood using a kit by Qiagen. Genotyping was performed using the ABI PRISM 7900 Sequence Detection System by TaqMan for allelic discrimination assay (Applied Biosystems). Genotyping was done using Assays–on Demand, and SNP Genotyping Products (Applied Biosystems). The reaction was amplified on a GeneAmp polymerase chain reaction system: cycling conditions were as follows: an enzyme heat activation step at 95°C for 10 min, 40 two-step amplification cycles at 95°C for 15 second for denaturation and a last heating step at 60°C for 1 min for annealing and extension. To assess genotyping reproducibility, a random ~20% selection of the samples was genotyped, again in three SNPs with 100% concordance.

Statistical Analysis

Genotypic and allelic frequencies were analysed as categorical variables. Hardy-Weinberg equilibrium was computed to the expected genotype distribution. Triglycerides, fasting insulin, HOMA-IR, and leptin values were log-transformed because of their skewed distributions. The one-way analysis of variance (ANOVA) was used to compare continuous variables expressed as the mean ± standard deviation (S.D.), while categorical variables were compared using the Chi-squared test. Successive multiple linear regression analyses, adjusted for potential confu-

Results

Segovia study sample characteristics

The clinical characteristics of the studied population are shown in Tables 1 and 2. One hundred and forty-nine participants were obese, and the remaining ones (438) were non–obese. Statistical significant differences were found for most of the clinical parameters when comparing obese against normal weight subjects, although only 2 hours glucose, fasting insulin and proinsulin, 2 hours insulin and proinsulin, HOMA-IR and fasting leptin could be considered of different significant clinical relevance between groups. Fasting visfatin and adiponectin were similar in both categories subjects (Table 1). Women showed lower mean values of WC, triglycerides, fasting glucose, HOMA-IR, fasting proinsulin and proinsulin 2 hours than men. However, fasting HDL-C, leptin and adiponectin levels were higher in women than men (Table 2).

Circulating visfatin levels and clinical parameters

Plasma visfatin levels were significantly higher in obese subjects with type 2 diabetes than in other categories of glucose tolerance: Normoglycaemia (NG): 9.69±3.77 ng/ml, prediabetes: impaired fasting glucose/impaired glucose tolerance (IFG/IGT): 9.61± 2.72 ng/ml, and Diabetes Mellitus (DM): 13.48± 9.66ng/ml; global p = 0.018, NG vs DM p = 0.007; IFG/IGT vs DM p = 0.016. This association between elevated visfatin levels and type 2 diabetes mellitus was
confirmed by a lineal regression analysis adjusted for gender, age, BMI, and WC ($\beta = 0.064$, 95%CI: 1.002–1.135, $p = 0.021$). No evidence of that association was found in non obese subjects ($\beta = 1.03$, 95% CI 0.89–1.19, $p = 0.067$).

### Genotype distributions and association study

Genotype distributions of the analyzed SNPs are shown in Table 3. None of the SNPs deviated significantly from the Hardy-Weinberg, and our genotype distributions are similar to those reported in the NCBI (National Center for Biotechnology Information) for European populations (http://www.ncbi.nlm.nih.gov/entrez/). The analysed SNPs were in Hardy–Weinberg’s equilibrium (data not shown). In order to detect some possible associations between these genetic variants of the visfatin gene, obesity and other glucose tolerance status-related disturbances, the association study was performed in two groups of obese and non-obese individuals. Evidence of some associations with insulin sensitivity-related parameters was detected in the subgroup of obese participants. The significant associations found by ANOVA were confirmed by linear regression analysis showing that, in obese participants, the genotype AA of the rs4730153 SNP was significantly associated with fasting glucose ($\beta = 10.84$, $p = 0.040$), fasting insulin ($\beta = 9.004$, $p = 0.003$) and HOMA-IR ($\beta = 0.173$, $p = 0.031$) after adjustment for gender, age, BMI and WC. We performed the same analysis excluding diabetic subjects and the results were similar. On the other hand, the obese individuals carrying the CC genotype of the rs11977021 SNP showed higher circulating levels of fasting proinsulin ($\beta = 4.231$, $p = 0.029$) after adjustment for the same variables. No evidence of these associations was found in the non-obese subgroup or between the analysed genotypes and the other metabolic parameters (data not shown).

### Table 1. Segovia Study Sample Characteristics: non-obese vs. obese subjects.

|                               | Non-Obese(N = 438) X(SD) | Obese Subjects(N = 149)X(SD) | p     |
|-------------------------------|--------------------------|-----------------------------|-------|
| Age (years)                   | 54 (12)                  | 59 (12)                     | <0.001|
| BMI (kg/m²)                   | 25.73 (2.63)             | 32.71 (2.84)                | <0.001|
| Waist circumference (cm)      | 86.73 (9.91)             | 100.86 (7.84)               | <0.001|
| SBP (mm Hg)                   | 123 (17)                 | 132 (18)                    | <0.001|
| DBP (mm Hg)                   | 77 (9)                   | 82 (8)                      | <0.001|
| Fasting glucose (mg/dl)       | 89 (29)                  | 95 (24)                     | 0.043 |
| 2h glucose (mg/dl)            | 109 (38)                 | 127 (51)                    | <0.001|
| Fasting Proinsulin (pmol/L)   | 8.93 (5.94)              | 14.25 (11.96)               | <0.001|
| 2h Proinsulin (pmol/L)        | 52.47 (40.86)            | 68.54 (39.22)               | <0.001|
| Fasting insulin (μU/ml)       | 12.18 (7.42)             | 17.40 (11.43)               | <0.001|
| HOMA index                    | 2.73 (2.23)              | 4.18 (3.54)                 | <0.001|
| Cholesterol (mg/dl)           | 210 (39)                 | 221 (40)                    | 0.003 |
| Triglycerides (mg/dl)         | 91 (54)                  | 124 (77)                    | <0.001|
| HDL-cholesterol (mg/dl)       | 63 (19)                  | 56 (16)                     | <0.001|
| LDL-cholesterol (mg/dl)       | 129 (34)                 | 141 (36)                    | <0.001|
| Fasting Visfatin (ng/dl)      | 9.74 (3.89)              | 10.12 (4.23)                | 0.296 |
| Fasting leptin (ng/ml)        | 9.24 (6.60)              | 19.06 (11.67)               | <0.001|
| Adiponectin (μg/ml)           | 10.86 (5.24)             | 10.55 (5.02)                | 0.541 |

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure. Continuous variables were compared by ANOVA and results are mean (standard deviation) S.D.

doi:10.1371/journal.pone.0153976.t001
Cardiovascular risk

The genotype AA of the rs4730153 SNP offers protection against CV risk either estimated by Framingham or SCORE charts in general population as well as in obese and non-obese (Table 4). No associations with CV risk were observed for the other studied SNPs (rs11977021, rs7789066).

Discussion

Most recently it has been demonstrated that the systemic visfatin-mediated nicotinamide adenine dinucleotide synthesis is necessary for β cell function [35]. In this study, we performed a...
genetic association analysis to investigate whether the visfatin gene is a candidate gene influencing glucose tolerance, obesity and CV risk. The results here reported show for the first time, that in obese adult population, the SNP rs4730153 is associated with insulin resistance as estimated by HOMA-IR regardless of BMI, WC, age and gender. Moreover, another SNP, namely rs11977021 is independently associated with serum proinsulin levels. On the other hand the genotype AA of the rs4730153 SNP seemed to be protective for CV risk in either Framingham or SCORE in general population as well as in obese and non-obese.

As for the significance of circulating visfatin levels, several authors [13, 14, 36] have reported higher circulating visfatin levels in type 2 diabetic subjects than in non diabetic individuals from Caucasian and non–Caucasian populations, though it was unclear if this association was primarily related to obesity. Moreover, no associations between insulin sensitivity related parameters and circulating visfatin levels have been found in most of the reported studies [13, 14, 37, 38] or, when they found significance, it was lost after adjusting for BMI [39]. Chen et al [40], in a case–control study on 120 non–obese individuals, reported higher plasma levels of circulating visfatin in patients with type 2 diabetes mellitus than in non diabetic subjects after adjustment for gender, age and BMI. Similarly, García-Fuentes et al [16] showed that plasma visfatin levels are increased in patients with severe obesity but only when it is accompanied by some degree of impaired glucose tolerance. Using the same EIA commercial kit (Phoenix Pharmaceuticals), we found that elevated visfatin levels were associated with a higher prevalence of type 2 diabetes mellitus just in obese subjects. However, the conclusions derived from our study and the above referred reports must have some limitations because of the specificity of this particular assay, as well as others currently available, has been recently questioned as the different immunoassays might detect distinct visfatin compounds [18].

On the other hand, the analysis of genetic variants in the visfatin gene might help knowing if visfatin plays an important physiological role in glucose homeostasis–related alterations [41]. We found that, in our obese subpopulation, the SNPs rs11977021 and rs4730153 are associated with glucose metabolism–related parameters regardless of BMI, WC, age and gender. As for the rs4730153 variant, the allele frequency was in agreement with that reported in other Caucasian populations [31, 42]. The homozygous subjects for the A allele had higher mean values of fasting glucose, fasting insulin and HOMA index. These associations have been previously explored in 626 subjects without type 2 diabetes mellitus [31] and in 167 obese and 508 non–obese children [41] from Germany, but no statistically significant associations were found. The physiological mechanism by which an intronic polymorphism such as the rs4730153 affects changes in glucose metabolism remains unclear. So far, there are only 2 SNPs located in the promoter region of the visfatin gene (-948C/A, rs9770242) which have been found to be associated with type 2 diabetes–related parameters [31, 32, 43], but no proof of its functionality is yet available. Of further interest is to consider that polymorphisms in the phosphoinositide 3–kinase gene is a potential candidate gene to develop type 2 diabetes [44] also located in the chromosome region 7q22.3.

Table 4. Cardiovascular risk according to SNP: rs4730143.

| SNP | rs4730153 | FRAMINGHAM |  |  |  | SCORE |  |  |
|-----|-----------|-------------|---|---|---|--------|---|---|
|     |           | < 20%       | > 20% |     |     | < 5%   | > 5% |     |
|     | Genotype  | n   | %  | n   | %  | n   | %  | n   | %  |
|     | GG        | 149 | 79.4 | 39 | 20.6 | 164 | 87.3 | 24 | 12.7 |
|     | GA        | 241 | 85.6 | 41 | 14.4 | 256 | 90.8 | 26 | 9.2  |
|     | AA        | 105 | 90  | 12 | 10  | 112 | 95.6 | 5  | 4.4  |
|     | p = 0.019 |     |     |     |     | p = 0.031 |     |     |

doi:10.1371/journal.pone.0153976.t004
The rs11977021 had been previously associated with total and LDL cholesterol [31] but its possible association with proinsulin has not been previously analysed. We report here a significant association between the CC genotype of the rs11977021 and higher levels of fasting proinsulin. This finding might be of relevance since there is data indicating that the rs11977021 variant might be a functional polymorphism key in type 2 diabetes mellitus [31].

On the other hand, in the last years, several studies have established positive associations between enhanced circulating visfatin/NAMPT levels and atherogenic inflammatory diseases, therefore supporting a role for visfatin as a potential biomarker of cardiovascular complications associated to metabolic disorders [45–47]. In another study, Belo et al [48] explored different SNPs (rs1319501 and rs3801266) in obese children and adolescence with and without ≥ 3 traditional metabolic risk factors (MRFs). They found that the SNPs rs1319501 had no effect on plasma visfatin levels in obese and obese children with ≥ 3 MRFs as compared to lean children. In contrast, rs3801266 was associated with higher plasma visfatin concentrations in lean and obese children but not in obese children with ≥ 3 MRFs, suggesting that obesity and MRFs are more influential than genetic polymorphisms in the determination of visfatin levels in obese children. Other study in obese Chinese children and adolescents [49] found that rs4730153 GG genotype polymorphism was related to an increase in insulin sensitivity and a decrease in triglycerides in response to exercise. So previous described results focused on obesity in earlier stages of life, need to be corroborated in larger studies and the comparison to our results here reported is difficult. Finally, Dou et al. [50] suggested that NAMPT may play an important role in the development of dilated cardiomyopathy. Our study shows that visfatin genotype AA SNP rs4730153 is associated with a lower estimated CV-risk, although the precise mechanism by which the SNP influence CV-risk remains to be established.

In summary, this is the first study which concludes that the genotype AA of the rs4730153 SNP appear to protect against CV events in obese and non-obese individuals, estimated by Framingham and SCORE charts. Our results confirm that the different polymorphism in the visfatin gene might be influencing the glucose homeostasis in obese individuals. Additional genetic studies in large obese population samples and functional characterization of the genetic variants are, however, warranted to corroborate our results.

Acknowledgments

The authors also wish to thank María Peiró-Camaró Adán who helped revise the English.

We gratefully acknowledge Members of the Segovia Insulin Resistance study Group (SIRSG) lead author: Manuel Serrano Ríos.e-mail: manuel.serrano@salud.madrid.org: Ángel Agudo-Benito, Juana Alonso-Barbolla, Eva M Álvarez-de Castro, Mónica Álvarez-González, María José Andrés-Francés, Paz de Andrés-Luis, Juan Manuel de Andrés-Rubio, Enrique Arrieta-Antón, Yolanda Artiñano-del Pozo, María de los Ángeles Benito-Benito, Pinal Benito-Zamarriego, Miguel Ángel Betés-Ruiz, Teresa Calvo-Navajo, Juan José Cañas-Sanz, Ovidio Campo-Hernández, María Jesús Cardiel-Mañas, Rosario Cayuela-Caravaca, Tomás Conde-Macias, Lucia Corral-Cuevas, Rafael Cuervo-Pinto, Máximo Durán-Ramos, Raúl Fernández-Lambea, Eva M García-Arahuetes, Eugenio P García-de Santos, Francisco J García-de Santos, José García-Velázquez, Luís García de Yébenes-Prous, Magdalena Garrido-Mesa, Esther González-Aispiri, Esther González-Garrido, Pedro González-Sastre, Luis Gonzálvez-López, Enrique Guilabert-Pérez, Argimiro Gutiérrez-Mata, Benito de la Hoz-García, Mariana Egidio-Martín, Belén Estampa-Santiago, Lucia Fuentes-Fuentes, José María García Arres, Belén García-Márquez, Julia García Múgica, Juan F Gil-García, Carmen González-Ferreiro, Mercedes Herranz-Rosa, María Carmen Herrero-de la Cruz, María de la Infanta-Pérez, Mariano Illana-Sanz, Jesús Izquierdo-Sánchez, Carlos de la Lama López-Areal, Ana M de Lucas-Herrero, José
Carlos Martín-Cuesta, Maria M Martín-García, Elena Martín-Muñoz, Elvira Martín-Tomero, Manuel Monsalve-Torrón, Agustín Moreno-Aragoneses, Vicente Negro-Dimas, Luis Ortega-Suárez, Felipe de la Osa-Plaza, José de Pablo-Álamo, José Luis Palacio, María Luz Pardo-Duque, Jesús Pérez-Tarrero, José M.ª Pinilla-Sánchez, Dolores Pihuela-de la Calle, Gloria Poza-Martín, Rosa Amparo Ramos-Herranz, María de los Ángeles Requejo-Grado, Laura Rincon-Heras, Javier Roca-Bernal, María Rodríguez-Herrera, José Rojas-Mula, Jesús Ruiz-Bario, Noelia Sánchez-Jiménez, Belén Sánchez-Martín, Luis A Santos-López, César Sanz-Herrero, Juan José Sanz-Vicente, Marina Silva-Guisasola, Virginia Silva-Guisasola, Carlos Solís-Camba, Carmen Tapia-Valero, Antonia Valverde-Martín, María del Pilar de Vega-Codes, Saturio Vega-Quiroga, Cristina Velarde-Mayol, Julio Zamarrón-Moreno and Laura Zamarrón-Sanz.

Collaborating centers (all in the Province of Segovia): Villacastín, El Espinar, Segovia I, Segovia II, Segovia III, Segovia Rural, Cantalejo, Carbonero el Mayor, Sacramena, Sepúlveda, Cuéllar, Nava de la Asunción, Riaza and San Ildefonso Primary Care Centers.

Author Contributions
Conceived and designed the experiments: MSR. Performed the experiments: ACA MTML MPB YLR. Contributed reagents/materials/analysis tools: MTML MPB YLR. Wrote the paper: MTML MSR ACA. Study concept and design: MSR. Acquisition of data: ACA MTML MPB YLR. Analysis and interpretation of data: CFP MTML MSR. Drafting of the manuscript: MTML MSR ACA. Analysis and interpretation of data: CFP MTML MSR.

References
1. Tilg H and Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clinical Science. 2008; 114: 275–288. doi:10.1042/CS20070196 PMID: 18194136
2. de Luis DA, Gonzalez Sagrado M, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle. Nutrition. 2010; 26: 1130–1133. doi:10.1016/j.nut.2008.11.019 PMID: 19211226
3. Sun Q, Li L, Li R, Yang M, Liu H, Nowicki MJ, et al. Over expression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Annals of Medicine. 2009; 41:311–320. doi: 10.1080/07853890902729760 PMID: 19263259
4. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clinical Endocrinology. 2009; 71 (2), 202–207. doi:10.1111/j.1365-2265.2008.03453.x PMID: 19178507
5. Garcia-Bermúdez M, González-Juanatey C, Rodríguez-Rodríguez L, Miranda-Filloy JA, Perez-Esteban S, Vazquez-Rodriguez TR, et al. Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 2011; 29: 681–688. PMID: 21906432
6. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol.1994; 14:1431–1437. PMID: 8289818
7. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of Insulin. Science. 2005; 307: 426–430. PMID: 15604363
8. Telejko B, Kuzmicki M, Zonenberg A, Szamatowicz J, Wawrusiewicz-Kurylonek N, Nikolajuk A, et al. Visfatin in gestational diabetes: Serum level and mRNA expression in fat and placental tissue. Diabetes Research and Clinical Practice. 2009; 84: 68–75. doi:10.1016/j.diabetres.2008.12.017 PMID: 19185944
9. Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection? Current Opinion in Pharmacology. 2008; 9: 202–207. doi:10.1016/j.coph.2008.10.005 PMID: 19081303
10. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin–like effects of visfatin on human osteoblasts. Calcif Tissue Int.2007; 80: 201–210. PMID: 17340225
11. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 2003; 544: 74–78. PMID: 12782293
12. Sethi JK, Vidal Puig A. (2005) Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 11: 344–7. PMID: 16005682
13. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism Clinical and Experimental. 2007; 56:1216–1220. PMID: 17697864
14. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, et al. Visfatin is an adipokine but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab. 2006; 91: 1181–1184. PMID: 16394088
15. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes. 2005; 54: 2911–2916. PMID: 16186392
16. García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego Pére- ales JL, et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity. 2007; 10: 2391–2395.
17. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med. 2006; 23: 967–73. PMID: 16922702
18. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrin Metab. 2007; 92: 4783–4791.
19. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Retraction. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2007; 318: 565.
20. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: a new player in mesangial cell physiology and diabetic retinopathy. Am J Physiol. 2008; 295: F1485–F1494.
21. Andrade-Oliveira V, Câmara NOS, Moraes-Vieira PM. Adipokines as Drug Targets in Diabetes and Underlying Disturbances. Journal of Diabetes Research. 2015: 681612. doi:10.1155/2015/681612. PMID: 25918733
22. Arya R, Blangero J, Williams K, Almasy L, Dyer TD, Leach RJ, et al. Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican americans. Diabetes. 2002; 51 (3): 841–847. PMID: 11872689
23. Lehman DM, Arya R, Blangero J, Almasy L, Puppala S, Dyer TD, et al. Bivariate linkage analysis of the insulin resistance syndrome phenol types on chromosome 7q. Hum Biol. 2005; 77: 231–46. PMID: 16201139
24. Cheng LS, Davis RC, Raffel LJ, Xiang AH, Wang N, Quiñones M, et al. Coincident linkage of fasting insulin and blood pressure to chromosome 7q in hypertensive hispanic families. Circulation. 2001; 104: 1255–1260. PMID: 11551876
25. Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL, López A, Fernández-Alvarez J, Rivir- iego J, et al. Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia. Med Clin (Barc). 2005; 125: 481–486.
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160–3167. PMID: 14578255
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentra- tion in man. Diabetologia. 1985; 28: 412–419. PMID: 3899825
28. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in non-diabetic population. Med Clin (Barc). 2001; 117: 530–533.
29. Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 18: 499–502.
30. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Bacquer D, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the Score project. Eur Heart J. 2003; 24 (11): 987–1003. PMID: 12788299
31. Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab. 2006; 91: 2725–2731. PMID: 16636125
32. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian popu- lation. Diabetes. 2006; 55: 2896–2902. PMID: 17003559
33. Tokunaga A, Miura A, Okachi Y, Segawa K, Fukuhara A, Okita K, et al. The 1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J. 2008; 55: 205–212. PMID: 18270432
34. Romacho T, Azcutia V, Yazquez-Bella M, Matesanz N, Cercas E, Nevado J, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009; 52: 2455–2463. doi:10.1007/s00125-009-1509-2 PMID: 19727662

35. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism. 2007; 6: 363–375. PMID: 17983582

36. López-Bermejo A, Chico-Juliá B, Fernández-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes. 2006; 55: 2871–2875. PMID: 17003355

37. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91: 3165–3170. PMID: 16234302

38. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation but not with insulin resistance. Clinical Endocrinology. 2007; 67: 796–800. PMID: 17634078

39. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism Clinical and Experimental. 2007; 56: 565–570. PMID: 17379018

40. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/Pre-B Cell Colony–enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91: 295–299. PMID: 17512309

41. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005; 30: 194–204. PMID: 15817396

42. Romacho T, Sanchez-Ferrer C, Peiro C. Visfatin/Nampt: An adipokine with cardiovascular impact. Mediators Inflamm. 2013; 2013:946427. doi:10.1155/2013/946427 PMID: 23447513

43. Körner A, Böttcher Y, Enigk B, Kiess W, Stumvoll M, Kovacs P. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism Clinical and Experimental. 2007; 56: 772–777. PMID: 17512309

44. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, Duffy J, et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity. 2006; 14; 2119–2126. PMID: 17189536

45. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circulation Journal. 2009; 73, (4): 595–601. PMID: 19225203

46. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007; 56, (4): 451–458. PMID: 17378999

47. Belo VA, Luizon MR, Lacchini R, Miranda JA, Lanna CM, Souza-Costa DC, et al. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity. Int J Obes (Lond).2015; 39(1):130–135.

48. Lai A, Peng Y, Zhou B, Zhang K, Lin J, Dai X, et al. Association of Nicotinamide Phosphoribosyltransferase (NAMPT) gene polymorphisms and of serum NAMPT levels with dilated cardiomyopathy in a Chinese population. Int J Mol Sci. 2015; 16 (9): 22299–22318. doi: 10.3390/ijms16092299 PMID: 26388889